Continue Reading
Full article on Unknown
Penumbra Stock Jumps. It’s Being Bought by Boston Scientific for $14.5 Billion.
Market Intelligence Analysis
AI-Powered
Why This Matters
Boston Scientific is acquiring Penumbra in a $14.5 billion deal, expanding its vascular medicine business through the addition of mechanical thrombectomy products.
Market Impact
Market impact analysis based on bullish sentiment with 90% confidence.
Sentiment
Bullish
AI Confidence
90%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Boston Scientific has agreed to acquire Penumbra in a cash-and-stock deal worth $14.5 billion. The addition of Penumbra which makes mechanical thrombectomy products for vascular procedures, expands Boston Scientific’s vascular medicine business. The deal values Penumbra at $374 a share, with stockholders able to choose either $374 in cash or 3.8721 shares of Boston Scientific common stock.
Original article published by
Unknown
on January 15, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.